ClinicalTrials.gov
ClinicalTrials.gov Menu

Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01987375
Recruitment Status : Terminated (logistics)
First Posted : November 19, 2013
Last Update Posted : December 21, 2017
Sponsor:
Information provided by (Responsible Party):
Eben Rosenthal, Stanford University

Brief Summary:
This study is an open label, single institution, Phase 1 dose-escalation study to determine the safety profile of cetuximab-IRDye800 used in subjects with head and neck squamous cell carcinoma (HNSCC) that undergo surgery with curative intent. Participants will be given a dose of an approved head and neck cancer drug (Cetuximab) along with an investigational study drug called Cetuximab-IRDye800. Cetuximab-IRDye800 is a drug that is given prior to surgery that attaches to cancer cells and appears to make them visible to the doctor when he uses a special camera during the operation. The investigators are evaluating whether or not the use of the study drug along with the special camera will better identify the cancer while patients are in the operating room.

Condition or disease Intervention/treatment Phase
Head and Neck Cancer Drug: Cetuximab-IRDye800 Phase 1

Detailed Description:
This study will be a conventional 3+3 phase I study evaluating three escalating dose levels of intravenous infusion of cetuximab-IRDye800 for patients who tolerate a 100 mg test/loading dose of unlabeled cetuximab as part of the screening process. Two cohorts will be added that do not include a 100 mg unlabeled test/loading dose of cetuximab, but will include a 10 mg test dose prior to enrollment. One cohort of 6 patients will be added that includes a 100 mg unlabeled test/loading dose of cetuximab and a fixed 50 mg dose of cetuximab-IRDye800.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Phase I, Open-label Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cetuximab-IRDye800 as an Optical Imaging Agent to Detect Cancer During Surgical Procedures
Study Start Date : November 2015
Actual Primary Completion Date : April 19, 2017
Actual Study Completion Date : April 19, 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Cetuximab

Arm Intervention/treatment
Experimental: Cetuximab-IRDye800 Participants
Participants who received the study drug cetuximab-IRDye800, following a loading dose of unlabeled cetuximab
Drug: Cetuximab-IRDye800
a single dose of the study drug following a single loading dose of unlabeled cetuximab




Primary Outcome Measures :
  1. Number of subjects in a cohort experiencing a DLT (gr 2 or greater AE considered at least possibly related to study drug & clinically significant by the PI) after receiving cetuximab conjugated to the optical dye IRDye800CW(cetuximab-IRDye800) [ Time Frame: 30 days post intervention ]

Secondary Outcome Measures :
  1. Number of subjects with identifiable cancer as compared to surrounding normal tissue by correlating fluorescence with histological evidence of tumor post receipt of cetuximab conjugated to the optical dye, IRDye800CW (cetuximab-IRDye800) [ Time Frame: One year post intervention ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck.
  2. Patients diagnosed with any T stage, any subsite within the head and neck that are scheduled to undergo surgical resection. Patients with recurrent disease or a new primary will be allowed.
  3. Planned standard of care surgery with curative intent for squamous cell carcinoma
  4. Age ≥ 19 years
  5. Have life expectancy of more than 12 weeks
  6. Karnofsky performance status of at least 70% or ECOG/Zubrod level 1
  7. Have acceptable hematologic status, coagulation status, kidney function, and liver function including the following clinical results:

    • Hemoglobin ≥ 9gm/dL
    • Platelet count ≥ 100,000/mm3
    • Magnesium, potassium and calcium greater than or equal than the lower limit of normal range per institution normal lab values
    • TSH <10 micro International Units/mL

Exclusion Criteria:

  1. Received an investigational drug within 30 days prior to first dose of cetuximab-IRDye800
  2. Had within 6 months prior to enrollment: MI, CVA, uncontrolled CHF, significant liver disease, unstable angina
  3. Inadequately controlled hypertension with or without current antihypertensive medications
  4. History of infusion reactions to cetuximab or other monoclonal antibody therapies.
  5. Women who are pregnant or breast feeding
  6. Patients who have a grade 2 or greater reaction with the test/loading cetuximab dose.
  7. Evidence of QT prolongation on pretreatment ECG (greater than 440 ms in males or greater than 450 ms in females).
  8. Lab values that in the opinion of the primary surgeon would prevent surgical resection.
  9. Patients receiving Class IA (quinidine, procanamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.
  10. Patients with TSH>11

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01987375


Locations
United States, California
Stanford University, School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Eben Rosenthal
Investigators
Principal Investigator: Eben Rosenthal, MD Stanford University

Responsible Party: Eben Rosenthal, Professor of Otolaryngology, Stanford University
ClinicalTrials.gov Identifier: NCT01987375     History of Changes
Other Study ID Numbers: ENT0049
First Posted: November 19, 2013    Key Record Dates
Last Update Posted: December 21, 2017
Last Verified: December 2017

Keywords provided by Eben Rosenthal, Stanford University:
HNSCC
Imaging

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms by Site
Neoplasms
Cetuximab
Antineoplastic Agents